Very early research of omalizumab (known as Xolair®), currently used for the treatment of asthma, shows the drug was well tolerated in people with systemic lupus erythematosus (SLE) and associated with improvement in disease activity. Larger randomized clinical trials are needed to assess efficacy for people with lupus. Continue to follow the Lupus Foundation of America for updates on omalizumab.
Lupus Foundation of America, Pennsylvania Delaware Valley Region
PO Box 2489
Philadelphia, PA 19147
215.517.5070
infopdv@lupus.org
There are multiple chapters near you. Select your preferred chapter.
Supporting lupus patients and advocates in Arizona.
Serving the District of Columbia, Maryland, and Northern Virginia.
Serving Kansas, Missouri, and Central & Southern Illinois
Serving north, central and west Texas, including Dallas/Fort Worth, San Antonio, Austin, El Paso, Lubbock, and surrounding areas
Serving Northern Illinois, Indiana, Iowa, Michigan, and Minnesota
Serving Connecticut, Massachusetts, Maine, New Hampshire, northern and central New Jersey, New York, Rhode Island, and Vermont
Serving Pennsylvania, Delaware and Southern New Jersey
Serving Houston, Beaumont, Corpus Christi, Harlingen and surrounding areas in Texas
There are multiple walks near you.
This website uses cookies to ensure you get the best experience. Learn more